GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Acasti Pharma
Acasti Pharma is a biopharmaceutical company whose stock price reflects its long and difficult history of clinical failures. The chart exemplifies the high risks of biotech, where the company is struggling to find new applications for its technologies after the failure of its lead drug.
Share prices of companies in the market segment - Heart
Acasti Pharma is a biopharmaceutical company focused on developing drugs for rare and orphan diseases. We've rated it "Heart," and the chart below shows how investors value companies in the specialty pharmaceuticals sector.
Broad Market Index - GURU.Markets
Acasti Pharma is a biopharmaceutical company developing drugs for the treatment of rare and orphan diseases. As a component of the GURU.Markets index, it represents the biotech sector. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
ACST - Daily change in the company's share price Acasti Pharma
For Acasti Pharma Inc., which develops drugs to treat cardiovascular diseases, daily volatility reflects sensitivity to clinical trial data. This metric is key for assessing risks in biotech.
Daily change in the price of a set of shares in a market segment - Heart
Acasti Pharma is a pharmaceutical company developing drugs to treat rare diseases, including cardiovascular diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing ACST stock performance.
Daily change in the price of a broad market stock, index - GURU.Markets
Acasti Pharma is a pharmaceutical company developing new drugs. Its shares, like many in the sector, are volatile and react to news about clinical trials. These scientifically driven movements are part of the overall stock market landscape.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Acasti Pharma
For Acasti Pharma Inc., its year-over-year performance is a story of its strategic pivot. Its market cap change over the past 12 months reflects its decision to focus on developing drugs for rare diseases after the failure of its previous cardiology programs. Its valuation is a bet on success in a new, narrower niche.
Annual dynamics of market capitalization of the market segment - Heart
Acasti Pharma is a late-stage biopharmaceutical company. Its stock performance is entirely dependent on clinical trial results and regulatory decisions. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector compared to big pharma.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Acasti Pharma, a biopharmaceutical company focused on rare diseases, is a niche player. Its year-over-year market capitalization reflects progress in the development and approval of its drugs. Success in one narrow area can lead to significant growth, regardless of the broader market.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Acasti Pharma
Acasti Pharma is a biopharmaceutical company. Its monthly performance is typical for the sector: it depends on progress in its scientific developments and clinical programs. News of the results of its rare disease drug trials are the main drivers.
Monthly dynamics of market capitalization of the market segment - Heart
Acasti Pharma is a biopharmaceutical company focused on developing drugs for the treatment of rare and severe cardiovascular diseases. The chart below reflects the general sentiment in the cardiac pharmaceutical sector, where the company is seeking its niche.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Acasti Pharma is a pharmaceutical company focused on rare diseases. Its shares move in sync with news about clinical trials and regulatory decisions. The company's performance is uncorrelated with the market and represents a high-risk bet on its scientific developments.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Acasti Pharma
Shares of Acasti Pharma, a biopharmaceutical company, are news-sensitive. Weekly price movements depend on the results of clinical trials of their drug candidates for rare diseases. The chart below shows how short-term scientific and regulatory events affect the valuation of the company's pipeline.
Weekly dynamics of market capitalization of the market segment - Heart
Acasti Pharma specializes in developing drugs for rare diseases. Shares of such companies often exhibit high volatility, reacting to regulatory decisions and clinical trial data. The chart clearly demonstrates this binary risk, typical of biotech.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Acasti Pharma is a biopharmaceutical company. This chart shows how its weekly performance is independent of the broader market. Its stock price movements are driven solely by news about the progress of its drug candidates' clinical trials, not by the S&P 500.
Market capitalization of the company, segment and market as a whole
ACST - Market capitalization of the company Acasti Pharma
The Acasti Pharma Inc. price chart tells the story of a biotech company finding its way after the failure of its omega-3 drug. Its market cap now reflects the valuation of its new developments in rare disease treatments. The dynamics illustrate a risky attempt to start over.
ACST - Share of the company's market capitalization Acasti Pharma within the market segment - Heart
Acasti Pharma's market share in cardiology is focused on developing omega-3 fatty acid-based medications. Its market share reflects the potential of its concentrated formulas for treating patients with high triglyceride levels, a significant risk factor for cardiovascular disease.
Market capitalization of the market segment - Heart
This chart shows the total market capitalization of pharmaceutical companies developing fatty acid-based drugs. Acasti Pharma is one such player. The dynamics in the chart reflect the high volatility and risks associated with clinical trials in this competitive field.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart depicts the market value of a company fighting cardiovascular disease with high-purity omega-3 fatty acids. Acasti Pharma's market capitalization is the valuation of its pharmaceutical developments. The line shows how a small company is fighting for its share of the vast and competitive cardiology industry.
Book value capitalization of the company, segment and market as a whole
ACST - Book value capitalization of the company Acasti Pharma
The graph below shows Acasti Pharma's scientific foundation. Its line reflects the value of intellectual property for drugs treating rare and orphan diseases. The trend reflects the company's clinical research activity, which has become its main asset since its strategy shift.
ACST - Share of the company's book capitalization Acasti Pharma within the market segment - Heart
Acasti Pharma's tangible assets are its R&D laboratories for developing omega-3 fatty acid-based drugs. The chart shows its share of this scientific infrastructure, which serves as the physical basis for its pharmaceutical innovations.
Market segment balance sheet capitalization - Heart
Biotechnology is a world of contrasts. The graph shows the enormous factories of pharmaceutical giants. Acasti Pharma, as a development company, has a more streamlined model. Its value lies in its intellectual property, not in the scale of production that is typical of the R&D stage.
Book value of all companies included in the broad market index - GURU.Markets
Acasti Pharma focuses on developing drugs for rare diseases. The company's assets are not massive manufacturing plants, but rather a portfolio of patents and clinical trials aimed at small but high-need patient groups. The chart below shows the financial impact of its investments in solving orphan diseases.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Acasti Pharma
Acasti Pharma is a pharmaceutical company focused on rare diseases. Its market capitalization is a measure of its pipeline and its strategy for acquiring and developing drugs for niche markets.
Market to book capitalization ratio in a market segment - Heart
Acasti Pharma Inc. is a pharmaceutical company specializing in developing drugs for rare diseases. Its value depends on the success of its clinical programs. This chart shows how its market valuation is essentially an option on future drug approval.
Market to book capitalization ratio for the market as a whole
Acasti Pharma is a pharmaceutical company focused on treating cardiovascular diseases. This chart shows how the market values their pipeline of drug candidates. Share price dynamics are heavily influenced by news about clinical trials and the company's strategic decisions.
Debts of the company, segment and market as a whole
ACST - Company debts Acasti Pharma
Acasti Pharma, a biopharmaceutical company, is leveraging its financial structure to develop drugs for rare diseases. After failures in cardiology, the company shifted focus, and this chart reflects its efforts to find a new successful niche, which requires funding for new clinical programs.
Market segment debts - Heart
Acasti Pharma is a biopharmaceutical company focused on treating rare diseases. This chart shows how its debt policy reflects its transition from omega-3 drug development to new areas, and how it manages its capital to fund clinical trials of its new drug candidates.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Acasti Pharma
Color Star Technology is a holding company with diversified and frequently changing interests, ranging from education to entertainment and metaverses. This chart shows its complex financial structure. Its debt levels may reflect funding for various, often speculative, technology initiatives.
Market segment debt to market segment book capitalization - Heart
Acasti Pharma is a pharmaceutical company focused on developing drugs for rare and orphan diseases. This chart compares its debt load to the overall market capitalization of the pharmaceutical sector. It shows how a small company finances its clinical research while striving to carve out a niche in the market.
Debt to book value of all companies in the market
Acasti Pharma is a pharmaceutical company focused on developing drugs for rare and orphan diseases. Working in this niche reduces competition but requires specialized expertise. This graph of total market debt helps understand the environment in which the company raises capital to advance its developments, which target small patient groups.
P/E of the company, segment and market as a whole
P/E - Acasti Pharma
This chart shows the valuation of Acasti Pharma, a biopharmaceutical company. The P/E ratio is likely irrelevant here. The company's valuation is based on the potential of its cardiovascular drug candidates, which represents a high-risk bet on clinical trial success.
P/E of the market segment - Heart
Acasti Pharma is a biopharmaceutical company focused on developing drugs for the treatment of rare and orphan diseases. Its lead candidates target conditions such as subarachnoid hemorrhage. This chart shows the average valuation for the cardiology sector, reflecting how investors value companies operating in the orphan disease market.
P/E of the market as a whole
Acasti Pharma is a pharmaceutical company focused on developing drugs for rare diseases. The company has undergone a transformation, shifting its focus away from cardiovascular diseases. This risk appetite chart helps understand how investors evaluate biotech companies undergoing strategic transformation.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Acasti Pharma
Acasti Pharma is a pharmaceutical company focused on developing drugs for the treatment of rare cardiovascular diseases. This chart reflects market expectations for the success of its clinical programs. Future revenue depends on regulatory approvals and the commercial potential of its drugs.
%20P%2FE%20Acasti%20Pharma&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Acasti-Pharma&v=1772618504870 "Chart of the company's future (projected) P/E Acasti Pharma")
Future (projected) P/E of the market segment - Heart
Acasti Pharma is focused on developing drugs for rare and orphan diseases. This chart is a barometer of market expectations. It shows how investors assess the potential of its clinical programs compared to other biopharmaceutical companies operating in the rare disease niche.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Heart&v=1772618504920 "Future (projected) P/E graph of the market segment - Heart")
Future (projected) P/E of the market as a whole
Acasti Pharma specializes in developing drugs for the treatment of rare and orphan cardiovascular diseases. The company's success depends on the results of clinical trials. The overall market environment, visible in this chart, influences investor willingness to fund pharmaceutical companies operating in highly specialized but important markets.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772618504949 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Acasti Pharma
Acasti Pharma is a pharmaceutical company focused on developing drugs for rare diseases. Its financial performance is currently driven by clinical trial costs. This chart illustrates the company's financial trajectory, where success depends on positive clinical data and subsequent regulatory approval.
Profit of companies in the market segment - Heart
Acasti Pharma specializes in the development and commercialization of drugs for the treatment of rare and orphan cardiovascular diseases. This chart, showing overall profitability in the pharmaceutical sector, highlights the potential of niche markets. Acasti's success in bringing drugs to market for specific patient groups has the potential to generate significant profits and transform lives.
Overall market profit
Acasti Pharma is a pharmaceutical company focused on developing drugs for rare diseases. Having shifted its focus from cardiovascular issues, the company is seeking its niche. Its story exemplifies how biotech companies adapt in pursuit of breakthrough discoveries.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Acasti Pharma
Acasti Pharma is a biopharmaceutical company focused on developing treatments for rare diseases. Future revenue projections are speculative and depend on the success of its clinical trials. Analysts are assessing the commercial potential of its developments.
%20profit%20of%20the%20company%20Acasti%20Pharma&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Acasti-Pharma&v=1772618505180 "Graph of future (projected) profit of the company Acasti Pharma")
Future (predicted) profit of companies in the market segment - Heart
Acasti Pharma specializes in developing drugs for rare and orphan cardiovascular diseases. This chart shows overall profitability forecasts for the cardiology sector. It helps understand how the company's focus on niches with unmet medical needs relates to overall trends in cardiac drug development.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Heart&v=1772618505235 "Graph of future (predicted) profits of companies in a market segment - Heart")
Future (predicted) profit of the market as a whole
Acasti Pharma is a pharmaceutical company focused on treating rare diseases. Its success is determined by progress in clinical trials. This chart, which shows overall market sentiment, is important to Acasti. During periods of increased risk appetite, companies in its sector find it easier to attract the necessary funding for costly trials.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772618505281 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Acasti Pharma
Acasti Pharma is a pharmaceutical company focused on developing drugs for rare diseases. This chart, plotting its market capitalization against near-zero revenue, reflects the valuation of its pipeline. It demonstrates investors' confidence that one of its drug candidates will successfully complete clinical trials and reach the market.
P/S market segment - Heart
Acasti Pharma is a pharmaceutical company specializing in developing drugs for the treatment of rare and orphan diseases. The company has a pipeline of candidates in various stages of clinical development. This chart reflects investor estimates of biotech revenue, demonstrating the level of expectations for Acasti's scientific potential and future products.
P/S of the market as a whole
Acasti Pharma is a pharmaceutical company focused on developing drugs for the treatment of rare and orphan diseases. This chart helps understand how the market values biotech companies operating in the orphan disease niche, where there is a high unmet medical need.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Acasti Pharma
Acasti Pharma is a pharmaceutical company focused on treating rare cardiovascular diseases. This chart shows the market's assessment of its potential future revenue from its pipeline of drugs. It reflects investor confidence in the success of its clinical programs and the commercial potential of its innovative therapies.
%20P%2FS%20Acasti%20Pharma&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Acasti-Pharma&v=1772618505516 "The graph of the company's future (projected) P/S Acasti Pharma")
Future (projected) P/S of the market segment - Heart
Acasti Pharma is a biopharmaceutical company focused on developing drugs for rare and orphan diseases. The chart shows the average estimated future sales in the cardiology sector. It helps understand how investors view the company's new strategy after discontinuing cardiovascular development and its current clinical programs.
%20P%2FS%20market%20segment%20graph%20-%20Heart&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Heart&v=1772618505558 "Future (projected) P/S market segment graph - Heart")
Future (projected) P/S of the market as a whole
Acasti Pharma (ACST) is a pharmaceutical company focused on developing drugs for rare diseases. Their future depends on the success of clinical trials and regulatory approval. This graph of general economic expectations is irrelevant for a company operating in a highly specialized field of medicine.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772618505600 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Acasti Pharma
Acasti Pharma is a late-stage pharmaceutical company. Currently, it has no stable sales revenue. It is focused on drugs for rare and orphan diseases. Future development of this pipeline will depend on the successful completion of clinical trials and regulatory approval.
Sales of companies in the market segment - Heart
Acasti Pharma is a pharmaceutical company focused on developing drugs for rare diseases. Following the sale of its cardiology business, its future revenue will depend on the success of its new candidates, which is typical for a biotech company undergoing transformation.
Overall market sales
Acasti Pharma Inc. is a pharmaceutical company focused on developing drugs for rare diseases. Its success depends on clinical trial results and regulatory approval. Demand for such drugs is not dependent on economic cycles, but the overall market environment, reflected in this chart, influences the availability of funding for long-term R&D projects in the pharmaceutical industry.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Acasti Pharma
Acasti Pharma is a biopharmaceutical company specializing in developing drugs for the treatment of rare cardiovascular diseases. Future revenue depends on the success of its clinical programs. This chart reflects analysts' long-term expectations for its pipeline.
%20sales%20of%20the%20company%20Acasti%20Pharma&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Acasti-Pharma&v=1772618505725 "Schedule of future (projected) sales of the company Acasti Pharma")
Future (projected) sales of companies in the market segment - Heart
Acasti Pharma is a biopharmaceutical company specializing in developing drugs for the treatment of rare and orphan diseases. This chart shows the outlook for the cardiology sector. It reflects the overall need for new treatments, including rare diseases, which is a strategic focus for Acasti.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Heart&v=1772618505756 "Schedule of future (projected) sales of companies in the market segment - Heart")
Future (projected) sales of the market as a whole
This chart illustrating pharmaceutical investments is important for Acasti Pharma. The company develops drugs for the treatment of cardiovascular diseases. Its ability to fund clinical trials and bring products to market depends on the influx of capital into the biotech sector.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772618505762 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Acasti Pharma
Acasti Pharma is a pharmaceutical company focused on developing drugs for rare diseases. This chart reflects its financial performance at the clinical trial stage. Future profitability depends on successful trial results, regulatory approvals, and a pricing strategy for niche markets.
Market segment marginality - Heart
Acasti Pharma is a biopharmaceutical company specializing in developing drugs for rare and orphan diseases. Profitability depends on the success of its clinical programs and regulatory approvals. This chart shows the average profitability in the pharmaceutical industry. It helps assess the potential of its developments in niche therapeutic areas.
Market marginality as a whole
Acasti Pharma is a pharmaceutical company focused on developing drugs for rare diseases. Its success depends entirely on clinical trial results and regulatory approval. This chart reflects the overall investment climate, which is crucial for attracting the funding needed to conduct expensive research.
Employees in the company, segment and market as a whole
Number of employees in the company Acasti Pharma
Acasti Pharma is a biopharmaceutical company focused on treating rare diseases. This chart reflects a compact team leading its drugs through clinical trials. The dynamics show how the company manages its resources, often after acquiring new assets, focusing on the most promising areas in its portfolio.
Share of the company's employees Acasti Pharma within the market segment - Heart
Acasti Pharma specializes in developing drugs for rare cardiovascular diseases. This chart shows the company's share of the total number of researchers in its therapeutic niche. This reflects its scientific focus and its shift from nutraceuticals to orphan drug development.
Number of employees in the market segment - Heart
Acasti Pharma is a pharmaceutical company developing drugs for the treatment of rare and orphan cardiovascular diseases. This chart, showing employment in the cardiac research sector, is important. The growing number of specialists focusing on rare diseases indicates increased scientific and commercial interest in these previously neglected areas.
Number of employees in the market as a whole
Acasti Pharma is developing drugs to treat cardiovascular diseases. This employment rate chart reflects the number of potential patients with access to health insurance. Growing employment ensures stable funding for the healthcare system, allowing for the introduction of new, more effective drugs to the market.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Acasti Pharma (ACST)
Acasti Pharma (ACST) is a pharmaceutical company developing omega-3-based drugs for the treatment of cardiovascular diseases. This chart shows the valuation of their R&D. The company's value comes from its patents on drug formulas, not its manufacturing capacity. A small team manages intellectual property with high potential value.
%20of%20the%20company%20Acasti%20Pharma%20(ACST)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Acasti-Pharma-ACST&v=1772618505959 "Chart of market capitalization per employee (in thousands of dollars) of the company Acasti Pharma (ACST)")
Market capitalization per employee (in thousands of dollars) in the market segment - Heart
Acasti Pharma focuses on developing drugs to treat rare diseases. Like many companies in this sector, it may not have revenue, but it does possess a valuable patent portfolio. This chart clearly demonstrates that market value in biotech is often an estimate of the future potential generated by a small but highly skilled team.
%20by%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Heart&v=1772618505963 "Market capitalization per employee (in thousands of dollars) by market segment - Heart")
Market capitalization per employee (in thousands of dollars) for the overall market
Acasti Pharma specializes in developing drugs for rare diseases. In this niche, even a product for a small group of patients can have a high price tag. This chart illustrates how a small, focused team can generate significant market value working in the field of orphan diseases.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772618505989 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Acasti Pharma (ACST)
Acasti Pharma is a biotech company that, after failing with an omega-3 drug, shifted its focus to developing drugs for rare diseases. This chart shows the "cost of rebooting" R&D: how much the company spends (negative profit) on each employee trying to bring its newly acquired drugs to the clinic.
%20Chart%20Acasti%20Pharma%20(ACST)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Acasti-Pharma-ACST&v=1772618506021 "Company Profit Per Employee (in thousands of dollars) Chart Acasti Pharma (ACST)")
Profit per employee (in thousands of dollars) in the market segment - Heart
Acasti Pharma is a pharmaceutical company specializing in the development of drugs for the treatment of rare and orphan diseases. While in clinical trials, the company incurs significant expenses. This chart allows us to assess how effectively it manages its capital. Future profitability depends on the successful commercialization of its developments.
%20in%20the%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Heart&v=1772618506090 "Chart of profit per employee (in thousands of dollars) in the market segment - Heart")
Profit per employee (in thousands of dollars) for the market as a whole
Acasti Pharma (ACST) is a biopharmaceutical company developing drugs to treat rare cardiovascular diseases. It is a clinical-stage R&D company with no profit. This metric, which is negative, reflects the "cost" of a single scientist working in the complex field of cardiology.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772618506221 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Acasti Pharma (ACST)
Acasti Pharma focuses on developing drugs for rare diseases. Following its shift in strategy, this chart shows how the company is attempting to commercialize its new assets. Its dynamics will be a key indicator of the success of its development and commercial efforts.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Acasti-Pharma-ACST&v=1772618506268 "Sales chart per company employee Acasti Pharma (ACST)")
Sales per employee in the market segment - Heart
Acasti Pharma is a clinical-stage biotech company focused on treating rare cardiovascular diseases. It's an R&D company with no commercial products. This chart clearly demonstrates that the productivity of their team of scientists and doctors is measured not by current sales, but solely by clinical trial success.
Sales per employee for the market as a whole
Innoviva (INVA) is an atypical company. It owns the royalty rights from leading respiratory drugs (for COPD/asthma) sold by GSK. Their business is collecting royalties. This chart demonstrates their maximum operating leverage. Innoviva has a very small staff, which simply manages these financial assets (royalties). Hundreds of millions in revenue accrue automatically, resulting in one of the highest revenue ratios.
Short shares by company, segment and market as a whole
Shares shorted by company Acasti Pharma (ACST)
Acasti Pharma (ACST) is a biotech company with a long history of cardiovascular drug failures that is attempting to reinvent itself. This chart tracks bearish bets. The shorts reflect market skepticism that the company's new project will be more successful than previous failures.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Acasti-Pharma-ACST&v=1772618506363 "Short Shares Chart for the Company Acasti Pharma (ACST)")
Shares shorted by market segment - Heart
Acasti Pharma (ACST) is a biopharmaceutical company specializing in cardiovascular drugs. The chart below represents a general short position in the biotech sector. It demonstrates investors' general skepticism about the success of risky clinical trials.
Shares shorted by the overall market
Acasti Pharma (ACST) is a clinical-stage biotech. Its value is based on future expectations. When this market fear indicator rises, investors' risk appetite evaporates. They are the first to sell speculative, loss-making biotechs like ACST in favor of safer assets.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Acasti Pharma (ACST)
This oscillator is a barometer of biotech speculation for Acasti Pharma. The company failed trials of its omega-3-based heart drug CaPre and is now seeking new assets for development. "Overheating" (above 70) occurs on announcements of the acquisition of a new drug. A history of declines keeps the shares "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Acasti-Pharma-ACST&v=1772618506495 "RSI 14 indicator chart for the company's stock Acasti Pharma (ACST)")
RSI 14 Market Segment - Heart
Acasti Pharma is a biotech company (Canada). Previously, they focused on *heart* (omega-3 from krill), now they're focusing on *rare* diseases. The "Heart" sector (biotech) thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It helps us understand: is ACST's volatility a "reversal" or is *the entire* biotech sector "overheated"?
RSI 14 for the overall market
Acasti Pharma (ACST) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ACST (Acasti Pharma)
Acasti Pharma (ACST) is a biopharmaceutical company focused on developing drugs for rare cardiovascular diseases. This chart shows the average 12-month forecast. It reflects analysts' speculative assessment of its clinical pipeline and the likelihood of new drug approvals.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ACST-Acasti-Pharma&v=1772618506582 "A chart showing analyst consensus forecasts for the expected stock price. ACST (Acasti Pharma)")
The difference between the consensus estimate and the actual stock price ACST (Acasti Pharma)
Acasti Pharma (ACST) is a biotech company focused on developing drugs to treat rare diseases, particularly subarachnoid hemorrhage. This chart shows the difference between the market valuation and the consensus estimate. It reveals whether experts believe in this niche, yet critical, R&D project.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ACST-Acasti-Pharma&v=1772618506603 "A chart showing the difference between the consensus forecast and the actual stock price. ACST (Acasti Pharma)")
Analyst consensus forecast for stock prices by market segment - Heart
Acasti Pharma is a biotech company that, following the failure of its omega-3 drug (a competitor to Vascepa), is trying to find new R&D targets. This chart shows general expectations for the cardiology sector, reflecting whether experts believe the company can "reboot."
Analysts' consensus forecast for the overall market share price
Acasti Pharma (ACST) is a clinical-stage biopharmaceutical company focused on cardiovascular disease. This is a high-risk scientific endeavor. This chart shows the overall risk appetite in the market. It serves as an indicator of the "open" or "closed" funding window for speculative biotechs seeking capital.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Acasti Pharma
Acasti Pharma is a biotech company that has rebooted itself. After their R&D on fish oil (for heart disease) failed, they acquired three (very early) drug candidates for rare diseases. This chart is a summary indicator of their second chance. It reflects their (very risky) new R&D pipeline and their desperate struggle to keep up with the money.
AKIMA Market Segment Index - Heart
Acasti Pharma is a biopharmaceutical company focused on cardiovascular diseases. They are developing new omega-3-based drugs for the treatment of conditions such as high triglyceride levels. This chart compares their composite index to their sector, showing how their approach to heart health compares to their competitors.
The AKIM Index for the overall market
Acasti Pharma is a biopharmaceutical company developing new drug delivery systems for rare diseases (ataxia-telangiectasia syndrome). This chart, which reflects the market average, provides a macro backdrop. It helps assess how ACST, which uses liquid spray technology, compares to overall economic trends.
